Mackenzie Financial Corp Reduces Stake in Edwards Lifesciences Co. (NYSE:EW)

Mackenzie Financial Corp lowered its position in Edwards Lifesciences Co. (NYSE:EW) by 42.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 92,082 shares of the medical research company’s stock after selling 67,034 shares during the period. Mackenzie Financial Corp’s holdings in Edwards Lifesciences were worth $7,021,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Castleview Partners LLC purchased a new stake in Edwards Lifesciences in the first quarter valued at approximately $25,000. Compass Wealth Management LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth approximately $31,000. Turtle Creek Wealth Advisors LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth approximately $34,000. Janiczek Wealth Management LLC boosted its position in Edwards Lifesciences by 108.6% in the 3rd quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company’s stock worth $40,000 after purchasing an additional 303 shares in the last quarter. Finally, Sunbelt Securities Inc. purchased a new stake in Edwards Lifesciences in the 1st quarter worth approximately $49,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on EW shares. OTR Global upgraded Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Citigroup upped their price objective on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. Mizuho upped their price objective on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Stifel Nicolaus increased their target price on Edwards Lifesciences from $70.00 to $83.00 and gave the company a “hold” rating in a research report on Wednesday, February 7th. Finally, Evercore ISI increased their target price on Edwards Lifesciences from $86.00 to $92.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $91.73.

Insider Transactions at Edwards Lifesciences

In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction on Monday, April 8th. The stock was sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the transaction, the vice president now owns 173,849 shares in the company, valued at approximately $16,049,739.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,506,925.92. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the completion of the sale, the vice president now owns 173,849 shares in the company, valued at $16,049,739.68. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock worth $17,166,254 in the last quarter. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 0.6 %

NYSE EW opened at $85.94 on Friday. The business has a fifty day moving average price of $90.15 and a 200 day moving average price of $78.37. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. The company has a market cap of $51.73 billion, a P/E ratio of 37.37, a P/E/G ratio of 4.29 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.64. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The business had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.50 billion. During the same period last year, the company earned $0.64 EPS. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. Research analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.